Jost's Engineering Company Limited Completes Divestment of 5...
31 Mar 2026
Jubilant Pharmova Limited has issued an important regulatory communication to shareholders regarding the impending transfer of unclaimed dividends and equity shares to the Investor Education and Protection Fund (IEPF) Authority. The company submitted this communication to BSE Limited and National Stock Exchange of India Limited on March 30, 2026, in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Regulatory Compliance and IEPF Transfer Requirements
Under Section 124(6) of the Companies Act, 2013, read with the IEPF Rules 2016, companies are mandated to transfer shares to the IEPF Authority when dividends remain unclaimed for seven consecutive years or more. The company has identified shareholders with unclaimed dividends from the financial year 2018-19, which are scheduled for IEPF transfer on October 31, 2026.
Parameter Details Transfer Due Date October 31, 2026 Claim Deadline May 15, 2026 Affected Period Financial Year 2018-19 onwards Legal Framework Section 124(6) of Companies Act, 2013
Shareholder Communication Details
The company has sent detailed notices to affected shareholders, covering multiple scenarios including regular unclaimed dividends and specific cases involving old share certificates. For shareholders holding old denominated share certificates from predecessor entities like Ramganga Fertilizers Limited, Vam Organic Chemicals Limited, and Jubilant Organosys Limited, the company has provided specific instructions for certificate exchange.
Documentation Requirements for Claims
Shareholders seeking to claim their unclaimed dividends must submit applications to Alankit Assignments Limited with the following documents:
Request letter duly signed by shareholders
Self-attested copy of PAN Card
Photocopy of blank cancelled cheque
Original share certificates (where applicable)
Impact on Shareholders and Corporate Benefits
Once shares are transferred to the IEPF Authority, all subsequent corporate benefits accruing on such shares will also be credited to the IEPF Authority. However, shareholders retain the right to claim both dividends and shares from the IEPF Authority by filing Form IEPF-5 and following prescribed procedures under the IEPF Rules.
Exemptions and Special Cases
The company clarified that shares will not be transferred to IEPF in cases where there are specific restraining orders from authorities or where shares are pledged or hypothecated under the Depositories Act, 1996. This provides protection for shareholders with legitimate encumbrances on their holdings.
The communication emphasizes the urgency of the matter, with Company Secretary Naresh Kapoor signing the official notice. Complete details of shares eligible for IEPF transfer are available on the company's website at www.jubilantpharmova.com , ensuring transparency in the process.
Jubilant Pharmova has announced that its Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025, at a meeting held on February 6, 2026. The pharmaceutical company has filed the consolidated and standalone financial results with stock exchanges and published them in newspapers for public access.
Board Meeting and Approval Process
The Board of Directors meeting was conducted on Friday, February 6, 2026, commencing at 10:30 A.M. and concluding at 12:35 P.M. The board approved both standalone and consolidated unaudited financial results for the third quarter and nine months period ended December 31, 2025, in accordance with Regulation 33 read with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The Audit Committee reviewed these results at its meeting held on February 5, 2026.
Meeting Parameter: Details Date: February 6, 2026 Duration: 10:30 A.M. to 12:35 P.M. Agenda: Q3FY26 financial results approval Audit Committee Review: February 5, 2026 Regulatory Compliance: Regulation 33 and 30 of SEBI LODR
Newspaper Publication and Public Access
Pursuant to Regulation 30 and Regulation 47 of the SEBI regulations, Jubilant Pharmova submitted copies of published financial results to stock exchanges on February 7, 2026. The company published Quick Response Codes and webpage details in Financial Express (English) and Jansatta & Hindustan (Hindi) newspapers dated February 7, 2026, providing investors easy access to complete financial results.
Publication Details: Information Submission Date: February 7, 2026 English Newspaper: Financial Express Hindi Newspapers: Jansatta & Hindustan Access Method: QR Code and webpage link Website Link: www.jubilantpharmova.com/Uploads/files/99q3stanfileResults.pdf
Regulatory Filings and Documentation
The company has filed comprehensive documentation with both BSE Limited and National Stock Exchange of India Limited. The filings include unaudited financial results for both standalone and consolidated operations, along with limited review reports from statutory auditors Walker Chandiok & Co LLP. The results are also accessible through stock exchange websites and the company's official website.
Filing Details: Information BSE Scrip Code: 530019 NSE Symbol: JUBLPHARMA Auditor: Walker Chandiok & Co LLP Review Date: February 6, 2026 Stock Exchange Access: www.nseindia.com , www.bseindia.com
Upcoming Investor Engagement
Jubilant Pharmova has scheduled physical investor and analyst meetings for February 9, 2026, in Mumbai to discuss the Q3FY26 earnings performance. The meetings, organized by Nuvama Institutional Equities as part of their India Conference 2026, will include 29 institutional investors from domestic and international asset management companies.
Investor Meeting: Details Date: February 9, 2026 Location: Mumbai Organizer: Nuvama Institutional Equities Participants: 29 institutional investors Purpose: Q3FY26 earnings discussion
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.
